JUL 20, 2021 1:00 PM PDT

Artificial Intelligence Predicts Which Drug Candidates Will Be Successful In Clinical Trials

WRITTEN BY: Ryan Vingum

Researchers are leveraging artificial intelligence and machine learning to help improve the rate at which drugs move successfully from preclinical to clinical development.

According to some research, the overall success rate of potential drug candidates is relatively low; only a small percentage of drug candidates move successfully out of the preclinical (nonhuman) testing stage, and many more fail during other clinical phases. Researchers note many reasons for these failures, though it is often an efficacy question: it may work great on mice in a lab, but that success doesn’t always translate well to an actual patient in a clinic. 

Given how costly it can be to develop a compound and move it through clinical trials, only to have it fail, it’s clear new approaches are needed. Researchers have responded by developing an artificial intelligence methodology at the Center for Precision Computational System Network (PreCSN) that may help predict and choose drug candidates that will be successful in trials.

This methodology, recently described in a Nature Communications article, helps researchers accurately, and with great detail, map a disease and evaluate a potential drug candidate before it even enters preclinical studies. Researchers used their methodology to explore a complex disease, inflammatory bowel disease (IBD) and analyzed extensive information about different gene expressions that could cause IBD, allowing them to map gene variations that were applicable to any IBD patient. 

Using this data collected from the program, researchers were able to select a viable drug candidate that could target a common feature of IBD, leaky-gut cells, and used it to conduct a “Phase 0” study, a pre-preclinical investigation of a drug candidate. Researchers tested this drug candidate by collecting cells from biopsies performed on IBD patients and growing them in a dish to imitate actual leaky-gut tissue. Results showed that the cells grown in a dish were responsive to the drug candidate, even though the experiment was performed ex vivo. Their approach further used additional data (existing FDA trials of drugs with similar targets) to make predictions about the potential future success of the drug, highlighting the benefit of the AI methodologies’ predictive power.

"In head-to-head comparisons, we demonstrated the superiority of this approach over existing methodologies to accurately predict 'winners' and 'losers' in clinical trials," said Pradipta Ghosh, MD, one of the lead authors of the study.

The authors of the study note that next steps include further clinical development of the AI-identified drug candidate, which may shed light on whether this methodology could be useful for other diseases. 

 

Sources: Science Daily; Nature Communications

About the Author
  • Writer and teacher with a background in professional writing and communication. Experience in higher education and writing for patient education and recruitment in the clinical research industry.
You May Also Like
APR 15, 2021
Technology
New Technique for Creating Nanofibers Could Help Produce Affordable, Effective Mask Filters to Combat COVID-19
APR 15, 2021
New Technique for Creating Nanofibers Could Help Produce Affordable, Effective Mask Filters to Combat COVID-19
Recently, nanofibers have been used to improve the filtration quality of protective face masks and help them filter airb ...
APR 04, 2021
Technology
How Can AI Prevent Future Pandemics?
APR 04, 2021
How Can AI Prevent Future Pandemics?
Researchers are looking into the versatility of artificial intelligence (AI) to prevent future pandemics. Scientists at ...
APR 20, 2021
Technology
New Artificial Muscle Technology
APR 20, 2021
New Artificial Muscle Technology
Scientists are always looking for ways to advance movements for robots. The adventure involves seeking new technologies ...
APR 22, 2021
Drug Discovery & Development
New Method To Fast Track Drug Development
APR 22, 2021
New Method To Fast Track Drug Development
The time it takes to respond to disease outbreaks is critical. But designing drugs to combat these disease outbreaks is ...
JUN 30, 2021
Clinical & Molecular DX
A Deep Learning Tool for Faster, Better Heart Disease Diagnoses
JUN 30, 2021
A Deep Learning Tool for Faster, Better Heart Disease Diagnoses
A new deep learning tool could help slash the time it takes to interpret cardiology scans to diagnose obstructive corona ...
AUG 02, 2021
Technology
A powerful combination: The Zeno trap and electron activated dissociation (EAD) fragmentation technology
AUG 02, 2021
A powerful combination: The Zeno trap and electron activated dissociation (EAD) fragmentation technology
Sensitivity is a fundamental performance characteristic of a mass spectrometer. Increasingly higher sensitivities are in ...
Loading Comments...